The EMPA-KIDNEY long term follow-up trial evaluated the effects of empagliflozin in patients with CKD. Findings showed that this treatment not only provided significant cardiorenal benefits during the active phase of the study but also maintained these positive effects for up to 12 months after treatment cessation.
Check out the visual abstract by Oscar Durón and join the conversation in our upcoming #NephJC.
